Clinical Trial

A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07489716
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 90 participants
Start Date 2026-04-29
Primary Completion 2028-08 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-13